89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

Mar 22

Brad Good has been an endorsed Squarespace Expert since the beginning and has been working on the platform since 2008. He has helped hundreds of Squarespace customers with their websites.

http://www.bradgood.net

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights